Engineered transaminase polypeptides for industrial biocatalysis
US-9617573-B2 · Apr 11, 2017 · US
US10604744B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10604744-B2 |
| Application number | US-201815945549-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 4, 2018 |
| Priority date | Feb 28, 2013 |
| Publication date | Mar 31, 2020 |
| Grant date | Mar 31, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
Opening claim text (preview).
What is claimed is: 1. A process for preparing a compound of structural Formula (I): having the indicated stereochemical configuration at the stereogenic center marked with an *; in an enantiomeric excess of at least 70% over the opposite enantiomer, wherein Z is OR 2 or NR 2 R 3 ; R 1 is C 1-8 alkyl, aryl, heteroaryl, aryl-C 1-2 alkyl, heteroaryl-C 1-2 alkyl, or a 5- to 6-membered heterocyclic ring system optionally containing an additional heteroatom selected from O, S, and N, the heterocyclic ring being unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C 1-4 alkoxy, and C1-4 alkyl, wherein alkyl and alkoxy are unsubstituted or substituted with one to five fluorines; R 2 and R 3 are each independently hydrogen, C 1-8 alkyl, aryl, or aryl-C 1-2 alkyl; or R 2 and R 3 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring system optionally containing an additional heteroatom selected from O, S, and N, the heterocyclic ring being unsubstituted or substituted with one to three substituents independently selected from oxo, hydroxy, halogen, C 1-4 alkoxy, and C 1-4 alkyl, wherein alkyl and alkoxy are unsubstituted or substituted with one to five fluorines; and the heterocyclic ring system being optionally fused with a 5- to 6-membered saturated or aromatic carbocyclic ring system or a 5- to 6-membered saturated or aromatic heterocyclic ring system containing one to two heteroatoms selected from O, S, and N, the fused ring system being unsubstituted or substituted with one to two substituents selected from hydroxy, amino, fluorine, C 1-4 alkyl, C 1-4 alkoxy, and trifluoromethyl; the process comprising the step of contacting a compound of structural Formula (II): with an engineered polypeptide having transaminase activity comprising an amino acid sequence having at least 90% sequence identity to the reference sequence of SEQ ID NO:2 and amino acid residue differences as compared to SEQ ID NO:2 of X155T/I/V/K/A/L, X42A/G and X328I, in the presence of an amino group donor in a suitable organic solvent under suitable reaction conditions. 2. The process of claim 1 , wherein the amino acid sequence of said engineered polypeptide having transaminase activity further comprises one or more residue differences as compared to SEQ ID NO:2, selected from: X5K, X33L, X36C, X41C/F/K/M/N/R, X44Q, X48D/E/G/K/T, X49T, X51K, X54P, X55L, X76S, X108V, X117G, X122F/Q, X148Q, X150A/F, X152S /T, X156Q/R/S, X160P, X164P, X165N, X182T, X215G/H/L, X218M, X241R, X267V, X270T, X273H, and X325M and X328I. 3. The process of claim 1 , wherein the amino acid sequence of said engineered polypeptide having transaminase activity further comprises one or more residue differences as compared to SEQ ID NO:2 of claim 1 , and further comprising: an amino acid residue difference as compared to SEQ ID NO:2 selected from G36C, I41C, I41F, I41K, I41M, I41N, I41R, P48D, P48E, P48G, P48K, P48T, A51K, S54P, M122F, M122Q, Y148Q, C152T, C215H, C215L, Y273H, L325M, and A241R; or a combination of residue differences selected from: A5K, S49T, S54P, C152S, and W156Q; P33L, I41C, S54P, S150F, C152S, F160P, and C215G; P33L, I41K, S54P, S150F, C152S, F160P, and C215L; P33L, P48G, S54P, S150F, C152S, and C215H; P33L, S54P, A109S, S150F, C152S, W156Q, and C215H; P33L, S54P, E117G, S150F, C152S, W156Q, and C215G; P33L, S54P, S150F, C152S, W156Q, and C215G; P33L, S54P, S150F, C152S, W156Q, and C215H; P33L, S54P, S150F, C152S, W156Q, C215H, and A241R; G36C, P48G, S54P, S150F, C152S, and C215H; G36C, P48K, S54P, S150F, C152S, and C215H; G36C, S54P, S150F, C152S, C215H, and A241R; G36C, S54P, S150F, C152S, and A241R; G36C, S54P, S150F, C152S, and C215H; I41C, S49T, S54P, S150F, C152S, F160P, C215G, and I267V; I41C, S49T, S54P, S150F, C152S, W156Q, C215G and I267V; I41C, S54P, I108V, S150F, and C152S; I41C, S54P, I108V, S150F, C152S, W156Q, C215G, and I267V; I41C, S54P, I108V, S150F, C152S, W156Q, and C215G; I41C, S54P, E117G, S150F, C152S, and F160P; I41C, S54P, E117G, S150F, C152S, and C215L; I41C, S54P, E117G, S150F, C152S, and C215L; I41C, S54P, S150F, C152S, and C215G; I41C, S54P, S150F, C152S, and C215L; I41C, S54P, S150F, C152S, W156Q, C215G, and I267V; I41C, S54P, S150F, C152S, F160P, C215G, and I267V; I41C, S54P, S150F, C152S, W156Q, F160P, and C215L; I41C, S54P, S150F, C152S, W156Q, and C215L; I41F, S54P, M122Q, S150F, C152T, W156Q, and C215G; I41F, S54P, S150F, C152S, W156Q, V171I, and C215G; I41F, S54P, S150F, C152S, W156Q, V171I, C215G, and A241R; I41F, S54P, S150F, C152S, W156Q, and C215G; I41K, P48E, S54P, S150F, C152S, and W156Q; I41K, P48E, S54P, S150F, C152S, and C215L; I41K, S54P, I108V, E117G, S150F, C152S, and C215L; I41K, S54P, I108V, S150F, C152S, and C215G; I41K, S54P, E117G, S150F, C152S, and C215G; I41K, S54P, E117G, S150F, C152S, C215L, and I267V; I41K, S54P, S150F, C152S, W156Q, and C215G; I41K, S54P, S150F, C152S, F160P, C215G, and I267V; I41K, S54P, S150F, C152S, and C215L; I41K, S54P, S150F, and C152S; I41K, S54P, S150F, C152S, and F160P; I41K, S54P, S150F, C152S, and C215G; I41K, S54P, S150F, C152S, C215G, and I267V; I41K, S54P, S150F, C152S, W156Q, and C215G; I41N, S54P, S150F, C152S, and F160P; I41N, S54P, E117G, S150F, C152S, and W156Q; I41N, S49T, S54P, S150F, C152S, F160P, D165N, and C215L; A44Q, S54P, I108V, S150F, C152S, and I267V; A44Q, S54P, I108V, S150F, and C152S; A44Q, S54P, I108V, S150F, C152S, and I267V; A44Q, S54P, S150A, and C152S; A44Q, S54P, S150F, and C152S; P48G, S54P, S150F, C152S, W156Q, and C215H; P48G, S54P, S150F, and C152S; S49T, S54P, I108V, E117G, S150F, C152S, F160P, and C215L; S49T, S54P, I108V, E117G, S150F, C152S, W156Q, and C215G; S49T, S54P, I108V, E117G, S150F, C152S, W156Q, C215G, and I267V; S49T, S54P, C152S, and W156Q; S54P, I55L, T126A, C152S, L218M, and A270T; S54P, F60V, S150F, C152S, W156Q, and C215G; S54P, T68A, S150F, C152S, W156Q, and C215G; S54P, T69S, S150F, C152S, W156Q, and C215G; S54P, N76S, T126A, C152S, S182T, L218M, A270T, and V328I; S54P, I108V, S150F, C152S, and C215H; S54P, I108V, S150F, and C152S; S54P, I108V, S150F, C152S, and I267V; S54P, I108V, S150F, C152S, W156Q, and F160P; S54P, E117G, C152S; S54P, E117G, C152S, and W156Q; S54P, M122Q, S150F, C152S, W156Q, C215G, and A241R; S54P, M122Q, S150F, C152S, W156Q, V171I, C215G, and A241R; S54P, M122Q, S150F, C152T, W156Q, V171I, C215G, and A241R; S54P, T126M, S150F, C152S, W156Q, and C215G; S54P, P135I, F136Y, S150F, C152S, W156Q, W192F, and C215G; S54P, F136I, S150F, C152S, W156Q, and C215G; S54P, F136I, S150F, C152S, W156Q, C215G, and G224I; S54P, F136I, S150F, C152S, W156Y, C215G, S282V, and G284I; S54P, F136I, S150F, C152S, W156Y, C215G, and G284P; S54P, F136Y, S150F, C152S, W156Q, C215G, S282V, and G284P; S54P, S150A, C152S, and I267V; S54P, S150F, C152S, W156Q, F160P, C215L, and I267V; S54P, S150F, C152S, W156Q, V171I, C215G, and A241R; S54P, S150F, C152S, W156Q, and C215L; S54P, S150F, C152S, F160P, and C215G; S54P, S150F, C152S, and C215H; S54P, S150F, C152S, and W156Q; S54P, S150F, C152S, W156Q, and I267V; S54P, S150F, C152S, W156Q, G193M, and C215G; S54P, S150F, C152S, W156Q, and C215G; S54P, S150F, C152S, W156Q, C215G, S282V, and G284I; S54P, S150F, C152S, W156Q, C215G, and T283S; S54P, S150F, C152S, W156Q, C215G, and G284I; S54P, S150F, C152S, W156Y, and C215G; S54P, S150F, C152S, and C215H; S54P, S150F, and C152S; S54P, S150F, C152S, C215G, and I267V; S54P, S150F, C152S, and I267V; S54P, S150F, C152S, W156Q, F160P, C215L, and I267V; S54P, S150F, C152S, W156Q, C215G, and I267V; S54P, S150F, C152S, and W156R; S54P, S150F, C152S, F160P, and C215L; S54P, S150F
Transaminases (2.6.1) · CPC title
Amines; Imines · CPC title
Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system (alloxazine or isoalloxazine, e.g. riboflavine C12P25/00) · CPC title
Ortho-condensed systems · CPC title
transferring nitrogenous groups (2.6) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.